Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAS-1 adjuvant + influenza HA antigen
- Development stage
- Unknown
- Lead developer
- Mercia Pharma
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MAS-1 adjuvant + influenza HA antigen is an investigational vaccine formulation combining MAS-1, a water-in-oil emulsion-based adjuvant/delivery system, with influenza hemagglutinin (HA) antigen. MAS-1 is characterized as a low viscosity, free-flowing emulsion comprised of stable nanoglobular aqueous droplets. This combination has demonstrated significant dose-sparing effects, allowing for reduced HA content while enhancing immunogenicity. Clinical trials have shown that MAS-1-adjuvanted influenza vaccines induce higher hemagglutination inhibition (HAI) antibody responses with prolonged durability (at least 6 months post-vaccination) compared to standard non-adjuvanted vaccines. The formulation also demonstrated enhanced cross-reactive antibodies against some non-study vaccine influenza viruses, suggesting broader protective immunity.
- Other names
- MAS-1-adjuvanted seasonal inactivated influenza vaccineMAS1-adjuvanted seasonal inactivated influenza vaccineMAS 1-adjuvanted seasonal inactivated influenza vaccineMAS-1 Adjuvanted IIVMAS1 Adjuvanted IIVMAS 1 Adjuvanted IIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on MAS-1 adjuvant + influenza HA antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAS-1 adjuvant + influenza HA antigen.